CytomX Therapeutics, Inc. (CTMX) Stock Score, Valuation & Financial Research
CytomX Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for CTMX
CytomX Therapeutics, Inc. currently has a Wall Street Score of 26/100. The stored market price is $2.77. Its financial score is 31/100. Its valuation score is 0/100. The latest WSS change is +0.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What CytomX Therapeutics, Inc. does
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials fo
CTMX financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $2.77
- Market capitalization:
- $601.9M
- Revenue:
- $18.3M
- Net income:
- $-79.7M
- Free cash flow:
- $-75.8M
- Cash:
- $17.2M
- Total debt:
- $5.7M
- EPS:
- -0.45
- Financial score:
- 31/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -0.8%.
- Free cash flow is $-75.8M, showing cash burn in the current stored period.
- The balance sheet shows $17.2M of cash versus $5.7M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.4 points: CTMX increased 0.4 points because Asset improved by 5 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 31/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CTMX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.